Kura Oncology, Inc. Appoints Kirsten Flowers as Chief Commercial Officer
January 06, 2020 at 07:30 am EST
Share
Kura Oncology, Inc. announced the appointment of Kirsten Flowers as Chief Commercial Officer. Ms. Flowers joins Kura most recently from Array Biopharma where she served as head of commercial operations until the completion of its $11.4 billion acquisition by Pfizer in July 2019.
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.